Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-Histidine Clear all
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 1, 2026, 2:48 PM EDT
Completed No phase listed Observational

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

NCT01694602
View directory record Official record
Conditions
Cachexia
Interventions
(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 1, 2026, 2:48 PM EDT
Completed No phase listed Observational

Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus

NCT00015639
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 1, 2026, 2:48 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Tildrakizumab on Epigenetic Age

NCT05110313
View directory record Official record
Conditions
Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions
TILDRAKIZUMAB
Biological
Lead sponsor
Carlos Wambier
Other
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 1, 2026, 2:48 PM EDT
Recruiting Phase 4 Interventional

HOPE Against Cancer Recurrence in HCC

NCT06717919
View directory record Official record
Conditions
Liver Transplantation, HCC, Oncological Outcomes
Interventions
Hypothermic oxygenated perfusion, Conventional cold storage
Procedure
Lead sponsor
Philipp Dutkowski
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 1, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional

Repletion of Ergothioneine in Patients With Kidney Failure

NCT06487546
View directory record Official record
Conditions
Esrd
Interventions
Ergothioneine, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

NCT03266965
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Carbidopa, L-Histidine
Drug · Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 1, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Not yet recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 1, 2026, 2:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 1, 2026, 2:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

NCT05042674
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Placebo, Ergothioneine, 25 miligrams, Ergothioneine, 25 miligrams, daily for 1 week
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 1, 2026, 2:48 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

NCT07700368
View directory record Official record
Conditions
Healthy Adult
Interventions
L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl)
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

SMART Diets for MASLD

NCT07459504
View directory record Official record
Conditions
Metabolic-dysfunction Associated Steatotic Liver Disease
Interventions
Essential Amino Acids Supplementation intervention, Low sugar diet
Drug · Other
Lead sponsor
Michigan State University
Other
Eligibility
11 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety of Graded-Dose of Histidine in Humans

NCT04142294
View directory record Official record
Conditions
Healthy
Interventions
Histidine
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 1, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

NCT01915212
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HSV529, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 1, 2026, 2:48 PM EDT